{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:17:48Z","timestamp":1762521468844,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint blockade (ICB) offers an in vivo approach to activate CD8\n                    <jats:sup>+<\/jats:sup>\n                    tumor-infiltrating lymphocytes (CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs) in cases of advanced non\u2013small cell lung cancer (NSCLC). A large fraction of NSCLC patients is unresponsive to ICBs and relapse due to the development of dysfunctional CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs with impaired cytotoxicity. Therefore, an improved understanding of regulator(s) that favor the development of cytotoxic T\n                    <jats:sub>eff<\/jats:sub>\n                    cells over dysfunctional CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs is required for the success of ICB therapy in NSCLC patients. Here, our metaVIPER-based scRNA-seq analysis of deep CD8\n                    <jats:sup>+<\/jats:sup>\n                    cell scRNA-seq data from 14 treatment-na\u00efve NSCLC patients revealed that the master regulon ZEB2 may drive CD8\n                    <jats:sup>+<\/jats:sup>\n                    differentiation along the cytotoxic effector trajectory in NSCLC tumors. In vitro, ZEB2 acts downstream of T-bet to stimulate lung tumor-reactive T\n                    <jats:sub>eff<\/jats:sub>\n                    cell differentiation. This T-bet\/ZEB2 axis displays immunotherapeutic effects on KP.SIY lung tumors independent of ICB therapy and mediates the therapeutic effects of murine serum albumin-fused IL-2\u2009+\u2009IL-12 combination immunotherapy (IL2-MSA\u2009+\u2009IL12-MSA) in mice. IL2-MSA\u2009+\u2009IL12-MSA operates through a parallel STAT4\/FOXO1-mediated mechanism that promotes CD8\n                    <jats:sup>+<\/jats:sup>\n                    TIL T-bet\/ZEB2 expression and lung tumor-reactive T\n                    <jats:sub>eff<\/jats:sub>\n                    cell differentiation. In conclusion, immunotherapeutic regimens that support ZEB2 activity in CD8\n                    <jats:sup>+<\/jats:sup>\n                    cells may show promise in NSCLC patients.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08112-y","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:09:18Z","timestamp":1762520958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The transcription factor ZEB2 mediates the antitumor efficacy of tumor-infiltrating lymphocytes in non\u2013small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6961-2190","authenticated-orcid":false,"given":"Jiajia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-8454","authenticated-orcid":false,"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beilei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongzhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8467-4559","authenticated-orcid":false,"given":"Depeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"8112_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","volume":"34","author":"E Brambilla","year":"2016","unstructured":"Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non\u2013small-cell lung cancer. J Clin Oncol. 2016;34:1223.","journal-title":"J Clin Oncol"},{"key":"8112_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-018-1080-0","volume":"35","author":"A Uryvaev","year":"2018","unstructured":"Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35:1\u20139.","journal-title":"Med Oncol"},{"key":"8112_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"8112_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205\u201314.","journal-title":"Cell"},{"key":"8112_CR5","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/2159-8290.CD-20-1285","volume":"11","author":"A Sinjab","year":"2021","unstructured":"Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, et al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. 2021;11:2506\u201323.","journal-title":"Cancer Discov"},{"key":"8112_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd5778","volume":"6","author":"P Gueguen","year":"2021","unstructured":"Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S, et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer. Sci Immunol. 2021;6:eabd5778.","journal-title":"Sci Immunol"},{"key":"8112_CR7","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1084\/jem.20190249","volume":"216","author":"J Clarke","year":"2019","unstructured":"Clarke J, Panwar B, Madrigal A, Singh D, Gujar R, Wood O, et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J Exp Med. 2019;216:2128\u201349.","journal-title":"J Exp Med"},{"key":"8112_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978\u201385.","journal-title":"Nat Med"},{"key":"8112_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi8800","volume":"6","author":"BL Horton","year":"2021","unstructured":"Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, et al. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non\u2013small cell lung cancer. Sci Immunol. 2021;6:eabi8800.","journal-title":"Sci Immunol"},{"key":"8112_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C, et al. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56:107\u201324.e105.","journal-title":"Immunity"},{"key":"8112_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature"},{"key":"8112_CR12","doi-asserted-by":"crossref","unstructured":"Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, et al. CD103+ CD8+ TRM cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep Med. 2020;1:100127","DOI":"10.1016\/j.xcrm.2020.100127"},{"key":"8112_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.immuni.2016.10.018","volume":"45","author":"C Gerlach","year":"2016","unstructured":"Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, et al. The chemokine receptor CX3CR1 defines three antigen-experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis. Immunity. 2016;45:1270\u201384.","journal-title":"Immunity"},{"key":"8112_CR14","doi-asserted-by":"crossref","unstructured":"Horton BL, D\u2019Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, et al. Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2. JCI Insight. 2023;8:e172728.","DOI":"10.1172\/jci.insight.172728"},{"key":"8112_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03843-3","volume":"9","author":"H Ding","year":"2018","unstructured":"Ding H, Douglass JrEF, Sonabend AM, Mela A, Bose S, Gonzalez C, et al. Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm. Nat Commun. 2018;9:1471.","journal-title":"Nat Commun"},{"key":"8112_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","volume":"37","author":"K Basso","year":"2005","unstructured":"Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37:382\u201390.","journal-title":"Nat Genet"},{"key":"8112_CR17","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1084\/jem.20150186","volume":"212","author":"CX Dominguez","year":"2015","unstructured":"Dominguez CX, Amezquita RA, Guan T, Marshall HD, Joshi NS, Kleinstein SH, et al. The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. J Exp Med. 2015;212:2041\u201356.","journal-title":"J Exp Med"},{"key":"8112_CR18","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1084\/jem.20150194","volume":"212","author":"KD Omilusik","year":"2015","unstructured":"Omilusik KD, Best JA, Yu B, Goossens S, Weidemann A, Nguyen JV, et al. Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. J Exp Med. 2015;212:2027\u201339.","journal-title":"J Exp Med"},{"key":"8112_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13056-x","volume":"10","author":"D Kobak","year":"2019","unstructured":"Kobak D, Berens P. The art of using t-SNE for single-cell transcriptomics. Nat Commun. 2019;10:5416.","journal-title":"Nat Commun"},{"key":"8112_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35264-8","volume":"14","author":"J-S Moon","year":"2023","unstructured":"Moon J-S, Younis S, Ramadoss NS, Iyer R, Sheth K, Sharpe O, et al. Cytotoxic CD8+ T cells target citrullinated antigens in rheumatoid arthritis. Nat Commun. 2023;14:319.","journal-title":"Nat Commun"},{"key":"8112_CR21","doi-asserted-by":"crossref","unstructured":"Ding Q-Q, Chauvin J-M, Zarour HM. Targeting novel inhibitory receptors in cancer immunotherapy. Semin Immunol. 2020;49:101436.","DOI":"10.1016\/j.smim.2020.101436"},{"key":"8112_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32:381\u20136.","journal-title":"Nat Biotechnol"},{"key":"8112_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.immuni.2020.04.007","volume":"52","author":"JJ Milner","year":"2020","unstructured":"Milner JJ, Toma C, He Z, Kurd NS, Nguyen QP, McDonald B, et al. Heterogenous populations of tissue-resident CD8+ T cells are generated in response to infection and malignancy. Immunity. 2020;52:808\u201324.e807.","journal-title":"Immunity"},{"key":"8112_CR24","doi-asserted-by":"crossref","unstructured":"Chen X, MacNabb BW, Flood B, Blazar BR, Kline J. Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia. Cell Rep. 2021;37:109991.","DOI":"10.1016\/j.celrep.2021.109991"},{"key":"8112_CR25","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1073\/pnas.212515299","volume":"99","author":"Q Ge","year":"2002","unstructured":"Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, et al. Soluble peptide\u2013MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci USA. 2002;99:13729\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8112_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.immuni.2018.03.015","volume":"48","author":"D Herndler-Brandstetter","year":"2018","unstructured":"Herndler-Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J, et al. KLRG1+ effector CD8+ T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity. Immunity. 2018;48:716\u201329.e718.","journal-title":"Immunity"},{"key":"8112_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0635-8","volume":"7","author":"C Lu","year":"2019","unstructured":"Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, et al. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J Immunother Cancer. 2019;7:1\u201311.","journal-title":"J Immunother Cancer"},{"key":"8112_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6794","volume":"6","author":"S Goossens","year":"2015","unstructured":"Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, et al. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015;6:5794.","journal-title":"Nat Commun"},{"key":"8112_CR29","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3324\/haematol.2018.207837","volume":"104","author":"S Goossens","year":"2019","unstructured":"Goossens S, Wang J, Tremblay CS, De Medts J, T\u2019Sas S, Nguyen T, et al. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms. Haematologica. 2019;104:1608.","journal-title":"Haematologica"},{"key":"8112_CR30","first-page":"2494","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer responsive to IL-12\/Stat4 and IFN\u03b3\/Stat1 signals. Blood J Am Soc Hematol. 2007;110:2494\u2013500.","journal-title":"Blood J Am Soc Hematol"},{"key":"8112_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","volume":"36","author":"RR Rao","year":"2012","unstructured":"Rao RR, Li Q, Bupp MRG, Shrikant PA. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation. Immunity. 2012;36:374\u201387.","journal-title":"Immunity"},{"key":"8112_CR32","doi-asserted-by":"crossref","unstructured":"Delpoux A, Marcel N, Michelini RH, Katayama CD, Allison KA, Glass CK, et al. FOXO1 constrains activation and regulates senescence in CD8 T cells. Cell Rep. 2021;34:108674.","DOI":"10.1016\/j.celrep.2020.108674"},{"key":"8112_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12:749\u201361.","journal-title":"Nat Rev Immunol"},{"key":"8112_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell\u2013like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med"},{"key":"8112_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.immuni.2010.06.014","volume":"33","author":"TC Wirth","year":"2010","unstructured":"Wirth TC, Xue H-H, Rai D, Sabel JT, Bair T, Harty JT, et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8+ T cell differentiation. Immunity. 2010;33:128\u201340.","journal-title":"Immunity"},{"key":"8112_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","volume":"27","author":"NS Joshi","year":"2007","unstructured":"Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281\u201395.","journal-title":"Immunity"},{"key":"8112_CR37","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.4049\/jimmunol.177.11.7515","volume":"177","author":"N Takemoto","year":"2006","unstructured":"Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL. Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol. 2006;177:7515\u20139.","journal-title":"J Immunol"},{"key":"8112_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12272-016-0736-6","volume":"39","author":"Y-J Lee","year":"2016","unstructured":"Lee Y-J, Won TJ, Hyung KE, Jang YW, Kim SJ, Lee DI, et al. IL-6 induced proliferation and cytotoxic activity of CD8+ T cells is elevated by SUMO2 overexpression. Arch Pharmacal Res. 2016;39:705\u201312.","journal-title":"Arch Pharmacal Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08112-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08112-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:09:31Z","timestamp":1762520971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08112-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8112"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08112-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"806"}}